Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.49 |
| ▸ | PLK1 | P53350 | 15/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 11/20 | 0.49 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14101194 | 0.87 | PLK1 (0.50) | BRD4PLK1BRDTVRK1RPS6KA3 | |
| SCHEMBL12956561 | 0.87 | RPS6KA3 (0.62) | BRD4PLK1BRDTVRK1RPS6KA3 | |
| SCHEMBL13104998 | 0.80 | BRD4 (0.72) | BRD4PLK1BRDTRPS6KA3PARP1 | |
| SCHEMBL12956560 | 0.77 | PLK1 (0.69) | BRD4PLK1BRDTRPS6KA3ALK | |
| SCHEMBL13104981 | 0.76 | RPS6KA3 (0.49) | BRD4PLK1BRDTVRK1RPS6KA3 | |
| SCHEMBL13104992 | 0.75 | PLK1 (0.76) | BRD4PLK1BRDTRPS6KA3ALK | |
| SCHEMBL862198 | 0.74 | RPS6KA3 (0.62) | BRD4PLK1BRDTVRK1RPS6KA3 | |
| SCHEMBL21527053 | 0.74 | RPS6KA3 (0.62) | BRD4PLK1BRDTVRK1RPS6KA3 | |
| SCHEMBL12957059 | 0.73 | BRD4 (0.44) | BRD4PLK1BRDT | |
| SCHEMBL862111 | 0.70 | PLK1 (0.77) | BRD4PLK1BRDTRPS6KA3PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7547780-B2 | Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7547780-B2 | Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20090018333-A1 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018333-A1 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20080319192-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-08 | — | — | US | disclosed |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-08 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319192-A1 | New dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DHCR7 | BRD4 4130/4885PLK1 4192/4885BRDT 4399/4885 |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | BRD4 4385/4885PLK1 4155/4885BRDT 4228/4885 |
| US-20090018333-A1 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | QDPR, DHPS, DHODH | BRD4 4409/4885PLK1 4325/4885BRDT 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.